Mabpharm kicks off $195m Hong Kong IPO
Biopharmaceutical company Mabpharm has launched the deal roadshow for its IPO and is targeting proceeds of up to HK$1.53bn ($194.7m).
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: